Current and Future Gene Therapy for Malignant Gliomas
- PMID: 12686720
- PMCID: PMC179758
- DOI: 10.1155/S1110724303209013
Current and Future Gene Therapy for Malignant Gliomas
Abstract
Malignant gliomas are the most common neoplasm in the central nervous system. When treated with conventional treatments including surgery, irradiation, and chemotherapy, the average life expectancy of the most malignant type, glioblastoma multiforme is usually less than 1 year. Therefore, gene therapy is expected to be an effective and possibly curative treatment. Many gene therapeutic approaches have demonstrated efficacy in experimental animal models. However, the current clinical trials are disappointing. This review focuses on current therapeutic genes/vectors/delivery systems/targeting strategies in order to introduce updated trends and hopefully indicate prospective gene therapy for malignant gliomas.
Figures
References
-
- Schoenberg B S. The epidemiology of central nervous system tumors. In: Walker M D, editor. Oncology of the nervous system. Martinus Nijhoff; Boston: 1983. pp. 1–30.
-
- Mahaley M S. Jr, Mettlin C, Natarajan N, Laws E R. Jr, Peace B B. National survey of patterns of care for brain-tumor patients. J Neurosurg. 1989;71(6):826–836. - PubMed
-
- Deen D F, Chiarodo A, Grimm E A, et al. Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program, National Cancer Institute. J Neurooncol. 1993;16(3):243–272. - PubMed
-
- Culver K W, Ram Z, Wallbridge S, Ishii H, Oldfield E H, Blaese R M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256(5063):1550–1552. - PubMed
-
- Trask T W, Trask R P, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther. 2000;1(2):195–203. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
